Lung Therapeutics raises $36M to trial pleural effusion drug by Nick Paul Taylor Wednesday, June 5, 2019 Lung Therapeutics has raised a $36 million series C round to take a treatment for a serious complication of pneumonia through phase 2 studies.
Bayer, Haplogen ink R&D deal for pulmonary diseases by Amirah Al Idrus Tuesday, August 14, 2018 Bayer and Evotec partner Haplogen will work to identify new treatments, such as antivirals, for pulmonary diseases.
Genoa scores $62M Series A to take IPF drug into the clinic by Nick Paul Taylor Monday, May 15, 2017 Genoa Pharmaceuticals has raised $62 million to take its lead candidate into the clinic.
